Company profile
Upstream Bio, Inc.
NASDAQ: UPB · Healthcare · Biotechnology
#762 of 1,418 Healthcare companies by revenue67th-percentile growth
EA Score
44DFH 49DQ 36GM —SS 45
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$3.2M
Rev growth YoY (TTM)
+16.0%
Net income (FY)
-$143.4M
Employees
75
as of 2026-08-12
Market cap
$385.8M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.9M$2.9M2025
Net income-$143.4M-$143.4M2025
Operating income-$160.4M-$160.4M2025
Total assets$353.8M$353.8M2025
Liabilities$14.0M$14.0M2025
Equity$339.8M$339.8M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Upstream Bio, Inc.’s revenue?
Upstream Bio, Inc. booked $2.9M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -5026.0% net margin.
Peers · Healthcare
SCWorx Corp.49DStemtech Corporation26DDental Patient Care America, Inc.73BMedical Supply International USA, Inc.——RxElite, Inc.——Absci Corporation47DNeighbors
Middlesex →Key facts
CEOE. Rand Sutherland
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: UPB
Employees75
IPO date2024-10-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.